Table 1 Summary of the pooled efficacy outcome
Outcome or subgroup | Studies | Cases | No. with event/total no. of patients INIs and EFV | Effect estimate (RR and 95% CI) |
|---|---|---|---|---|
Virologic suppression | 3 | 672 | 231/350 and 223/322 | 0.94 (0.85,1.05) |
 DTG vs. EFV | 1 | 113 | 52/69 and 36/44 | 0.92 (0.76,1.12) |
 RAL vs. EFV | 2 | 559 | 179/281 and 187/278 | 0.95 (0.84,1.07) |
Bacteriology suppression | 3 | 672 | 313/350 and 288/322 | 1.00 (0.95,1.05) |
 DTG vs. EFV | 1 | 113 | 61/69 and 40/44 | 0.97 (0.86,1.10) |
 RAL vs. EFV | 2 | 559 | 252/281 and 248/278 | 1.01 (0.95,1.06) |
Adherence | 3 | 617 | 309/321 and 291/296 | 0.98 (0.95,1.01) |
 DTG vs. EFV | 1 | 99 | 56/58 and 38/41 | 1.04 (0.94,1.15) |
 RAL vs. EFV | 2 | 518 | 253/263 and 253/255 | 0.97 (0.94,1.00) |